Pre-market price: 20.48, trading just above S1 support (20.16); downside opens toward S2 (19.43) if 20.16 breaks.
MACD histogram at -0.395 and still below zero: bearish momentum remains, though the negative histogram is contracting (selling pressure may be easing, not reversing yet).
RSI(6) ~32.9: nearing oversold/weak territory, consistent with a depressed bounce-prone area but not a confirmed reversal signal.
Moving averages converging: consolidation/transition phase; needs a reclaim of pivot 21.33 to shift near-term trend constructive.
Key levels: Resistance at 21.33 (pivot) then 22.51; Support at 20.16 then 19.43.
Pattern-based outlook provided: ~60% chance of -0.86% next day, -1.7% next week, -2.54% next month (near-term bias still down).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning/sentiment from open interest is bullish-leaning: put/call OI ratio 0.21 (calls dominate OI).
However, trading activity is extremely light (today’s total volume ~2; call volume 0, put volume 2), so the sentiment read is low-confidence.
Implied vol is elevated (30D IV 94.71) vs historical vol (59.6): options are pricing large moves; premium is expensive.
IV trend: 5D/10D IV averages (101.8/100.5) above current, implying IV has cooled slightly but remains high.
Open interest today 261; activity vs average OI shows elevated attention, but without volume confirmation.
Technical Summary
Sell
5
Buy
9
Positive Catalysts
supports scalability narrative.
Neutral/Negative Catalysts
with MACD below zero.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: $22.589M, +31.37% YoY (solid growth).
Profitability is improving but still negative: Net income -$13.465M (29.26% YoY improvement), EPS -0.37 (19.35% YoY improvement).
Takeaway: healthy top-line growth and improving losses, but not yet profitable; execution into the next earnings (2026-02-26) is key.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: bullish and improving—two firms reiterated Buy and raised price targets in December 2025.
TD Cowen (2025-12-09): PT raised to $29 from $20; Buy maintained; cited FDA clearance and earlier-than-expected expansion of addressable market.
Canaccord (2025-12-17): PT raised to $30 from $29; Buy maintained; constructive med-tech sector view.
Wall Street pros: FDA-driven TAM expansion narrative + strong margins + strong revenue growth.
Wall Street cons: still operating at a loss; execution risk into upcoming earnings; current price action hasn’t confirmed a trend reversal.
Ownership/flows: Hedge funds neutral (no significant last-quarter trend); insiders neutral (no significant last-month trend).
Influential/political activity: No recent congress trading data available in the last 90 days (no politician signal to lean on).
Wall Street analysts forecast CBLL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBLL is 25.17 USD with a low forecast of 17 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast CBLL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBLL is 25.17 USD with a low forecast of 17 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.340
Low
17
Averages
25.17
High
30
Current: 19.340
Low
17
Averages
25.17
High
30
Canaccord
Buy
maintain
$29 -> $30
AI Analysis
2025-12-17
Reason
Canaccord
Price Target
$29 -> $30
AI Analysis
2025-12-17
maintain
Buy
Reason
Canaccord raised the firm's price target on Ceribell to $30 from $29 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.
TD Cowen
Buy
maintain
$20 -> $29
2025-12-09
Reason
TD Cowen
Price Target
$20 -> $29
2025-12-09
maintain
Buy
Reason
TD Cowen raised the firm's price target on Ceribell to $29 from $20 and keeps a Buy rating on the shares after the company announced that it has received FDA 510(k) clearance for its delirium monitoring solution. The clearance, making its system the first and only U.S.-approved device for delirium screening and monitoring, comes months ahead of expectations and will significantly expand the company's total addressable market for adult seizure detection, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CBLL
